AveXis Inc., a Bannockburn-based gene therapy company developing treatments for patients with rare and life-threatening neurological genetic diseases, recently named Daniel Welch, Terrence Kearney and Frank Verwiel to its board of directors.
Welch is serving as non-executive chairman.
“The addition of these three industry leaders to our board of directors brings extensive corporate operating expertise to our board,” AveXis President and CEO Sean Nolan said. "These highly accomplished individuals will bring a wealth of operational, financial and strategic acumen to our board, as well as extensive experience in building companies from clinical-stage drug development to larger scale global commercialization. I know their impact will be immediate as we work to achieve our goal of fulfilling unmet treatment needs for patients suffering from rare, life-threatening neurological genetic diseases.”
Welch has more than 35 years of health care experience with multinational pharmaceutical and biotechnology companies. He is an executive partner at Sofinnova Ventures and previously served as president CEO and a director of InterMune Inc. Welch also serves on the boards of directors of Seattle Genetics Inc.; Ultragenyx Pharmaceutical Inc., where he also serves as chairman; and Intercept Pharmaceuticals Inc.
Kearney has more than 30 years of global health care experience with key pharmaceutical and life-sciences companies. He has served as CEO for Hospira Inc. and spent 25 years working in financial management roles at Abbott Laboratories. Kearney also serves on the boards of directors of Vertex Pharmaceuticals, Innoviva and Acceleron Pharma.
Verwiel has more than 25 years of experience working in the pharmaceutical industry, most recently as president, CEO and member of the board of directors of Aptalis Pharma Inc. He also held international management positions at Servier Laboratories and Merck & Co. He previously served on the boards for InterMune Inc. and the Biotechnology Industry Organization. Verwiel also serves on the boards of directors of Achillion Pharmaceuticals Inc. and Obseva SA.